Archive: 11/09/2012

Vandetanib in thyroid cancer: No proof of added benefit

Vandetanib (trade name Caprelsa) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health ...

Nov 09, 2012
popularity 0 comments 0

New mechanism of action for PARP inhibitors discovered

New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has led ...

Nov 09, 2012
popularity 0 comments 0